

Figure e-1. *Proportions of patients meeting the ab-inclusion criteria.* Patients in the rituximab-cohort (**A**) and in the control-cohort (**B**) are categorized for meeting the ab-criteria as defined in the methods section (NMDAR-abs detected in serum by CBA confirmed by IHC (in the absence of confirmatory IHC in serum only CBA serum titers of >1:500 were considered specific) and/or CSF-positive; GAD-abs >1:500 in CBA or >2000IE/ml in ELISA or RIA in serum and/or CSF-positive; LGI1-abs at any titer in CSF and/or serum; CASPR2-abs >1:128 in serum and/or CSF-positive [20] with only IgG-abs considered as relevant).